Corvus Pharmaceuticals Inc (CRVS): The situation you describe is pretty com...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	10
Posts	477
Boards Moderated	0
Alias Born	02/10/2006

flatlander_60048

Re: kenyonn2000 post# 204

Thursday, 03/30/2023 1:04:14 PM

Thursday, March 30, 2023 1:04:14 PM

The situation you describe is pretty common with a lot of innovative types. I agree that the focus seems to be constantly shifting. Remember 006 use for Covid? I think focusing on 818 use for T-Cell Lymphoma is the right target. The SOC (chemo) has a miserable PFS rate and it tears down the immune system. So a positive registration trialfor 818 has the potential to launch a front line treatment before the patients immune system and ACL threshold is decimated. CRVS needs to execute a positive mtg with FDA and land a decent partnership. If Miller is correct and 818 has application for solid tumors, immune disorders, etc., the licensing of one indication to bring in the cash infusion will be seen as well worth it.

Hopefully others from Yahoo board follow. Not sure what business model they are following but the dissatisfaction level is off the charts.

Regards FL.